Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Abcellera Biologics Inc reports results for the quarter ended in September - Earnings Summary

* Abcellera Biologics Inc  ABCL.OQ  reported a quarterly
adjusted
loss of 10 cents​​ per share for the quarter ended in September,
lower than the same quarter last year, when the company reported
EPS of 8 cents.  The mean expectation of nine analysts for the
quarter was for a loss of 13 cents per share. Wall Street
expected results to range from -20 cents to -10 cents per share.
    * Revenue fell 93.5% to $6.60 million from a year ago;
analysts
expected $11.84 million. 
    * Abcellera Biologics Inc's reported EPS for the quarter was
a
loss of 10 cents​.
    * The company reported a quarterly loss of $28.61 million.
    * Abcellera Biologics Inc shares had fallen by 10.4% this
quarter and lost 59.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 4% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Abcellera
Biologics Inc is $24.50 
This summary was machine generated from LSEG data November 2 at
09:39 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.13          -0.10          Beat
 Jun. 30 2023      -0.13          -0.11          Beat
 Mar. 31 2023      -0.14          -0.14          Met
 Dec. 31 2022      -0.01          -0.10          Missed

Recent news on AbCellera Biologics

See all news